Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MISTIC: Comparative Effectiveness of Therapies for MIS-C
NCT04898231Phase 3Completed
- Sponsor
- University of California, San Diego
- Start
- Dec 2020
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 3 trial of infliximab, methylprednisolone injection, anakinra in multisystem inflammatory syndrome (MIS), sponsored by University of California, San Diego. Started Dec 2020; status: completed.
02
Drugs
infliximabmethylprednisolone injectionanakinra
03
Conditions
multisystem inflammatory syndrome (MIS)
Beyond the preview
Go deeper on NCT04898231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04898231.